$118.38▾ 1.19%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$0.86cash per $1 profit
Healthy
Most of its reported profit shows up as real cash.
Valuation
4th pctvs its own history
Cheap
Its valuation sits in the cheaper end of its own recent range.
Revenue growth
+59.0%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Incyte Corporation turns 86¢ of every reported profit-dollar into real cash. Most of its reported profit shows up as real cash. Revenue is growing strongly year over year. Its valuation sits in the cheaper end of its own recent range.
Key numbers
Valuation
EPS (TTM)$8.43
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin31.1%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$5.53B
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Sentiment · last 30 days29 articles
18 bullish11 neutral0 bearish
[Latest] Global gRNA Market Size/Share Worth USD 2950 Million by 2034 at a 19% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
AI Disruption Reshapes Bioinformatics: Record Investment and Breakthrough Tools Signal a New Era for Drug Discovery and Precision Medicine
State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?
XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?
VHT vs. PBE: Which Health Care ETF Is the Better Buy?
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.